UT MD Anderson shared on LinkedIn:
“At this year’s annual meeting of Society for Immunotherapy of Cancer (SITC), UT MD Anderson experts showcased early-phase clinical trials and preclinical studies exploring new approaches to treating advanced cancers, including solid tumors, brain cancer and melanoma.
These studies offer new insights to improve the effectiveness of immunotherapies and expand treatment options for patients.
You can also read: Samik Upadhaya Shares Key Takeaways from SITC 2026 in Phoenix
